

## SUPPLEMENTAL MATERIAL

Anti-NMDA-receptor GluN1 antibody serostatus is robust in acute severe stroke

Pia S. Sperber<sup>1,4</sup>, Benjamin Hotter<sup>1,4</sup>, Matthias Endres<sup>1,3-5</sup>, Harald Prüss<sup>1,6</sup>, Andreas Meisel<sup>1,3-5</sup>

<sup>1</sup>Charité-Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Neurology, Berlin, Germany

<sup>2</sup>Experimental and Clinical Research Center, a cooperation between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

<sup>3</sup>Charité – Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Neuroscience Clinical Research Center, Germany

<sup>4</sup>Germany Center for Cardiovascular Diseases (DZHK), partner site Berlin, Berlin, Germany

<sup>5</sup>Charité – Universitätsmedizin Berlin, corporate member of Freie Universität and Humboldt-Universität zu Berlin, Center for Stroke Research Berlin, Germany

<sup>6</sup>German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany

*Corresponding author:*

Pia Sophie Sperber (MD)

Department of Neurology with Experimental Neurology

pia.sperber@charite.de

ORCID: 0000-0002-9534-2374


Charitéplatz 1, D-10117 Berlin, Germany

Supplemental Table S1: Characteristics of stroke patients with a stable titer and those with a fluctuating titer

Patients with	Stable titer (N=9)	Fluctuating titer (N=4)
<b>age</b> mean (SD)	73.3 (12.5)	80.3 (7.80)
<b>sex</b>		
Female	1 (11.1%)	3 (75.0%)
Male	8 (88.9%)	1 (25.0%)
<b>NIHSS baseline</b> median [Min, Max]	15.0 [10.0, 32.0]	14.0 [11.0, 20.0]
<b>mRS baseline</b> median [Min, Max]	5.00 [2.00, 5.00]	4.50 [4.00, 5.00]
<b>mRS before stroke</b> median [Min, Max]	0 [0, 3.00]	0 [0, 3.00]

Patients with	Stable titer (N=9)	Fluctuating titer (N=4)
<b>previous stroke</b>		
yes	3 (33.3%)	1 (25.0%)
no	5 (55.6%)	3 (75.0%)
Missing	1 (11.1%)	0 (0%)
<b>arterial hypertension</b>		
yes	9 (100%)	4 (100%)
no	0 (0%)	0 (0%)

Supplemental Figure 1: Anti-NMDA-IgM titer levels over up to 7 consecutive measurement



Supplemental Figure 2: Anti-NMDA-IgA titer levels over up to 7 consecutive measurement

